Package 68001-519-03

{"route": ["ORAL"], "spl_id": "2a90f7e8-2e30-7358-e063-6394a90a71a9", "openfda": {"upc": ["0368001520041", "0368001519045"], "unii": ["ZG7E5POY8O"], "rxcui": ["993541", "993557"], "spl_set_id": ["5ccec958-998d-43a1-86fb-eb2b5e697b77"], "manufacturer_name": ["BluePoint Laboratories"], "is_original_packager": [true]}, "finished": true, "packaging": [{"sample": false, "description": "500 TABLET, EXTENDED RELEASE in 1 BOTTLE (68001-519-03)", "package_ndc": "68001-519-03", "marketing_start_date": "20211213"}, {"sample": false, "description": "30 TABLET, EXTENDED RELEASE in 1 BOTTLE (68001-519-04)", "package_ndc": "68001-519-04", "marketing_start_date": "20211213"}, {"sample": false, "description": "90 TABLET, EXTENDED RELEASE in 1 BOTTLE (68001-519-05)", "package_ndc": "68001-519-05", "marketing_start_date": "20211213"}], "brand_name": "BUPROPION HYDROCHLORIDE", "product_id": "68001-519_2a90f7e8-2e30-7358-e063-6394a90a71a9", "dosage_form": "TABLET, EXTENDED RELEASE", "pharm_class": ["Aminoketone [EPC]", "Dopamine Uptake Inhibitors [MoA]", "Increased Dopamine Activity [PE]", "Increased Norepinephrine Activity [PE]", "Norepinephrine Uptake Inhibitors [MoA]"], "product_ndc": "68001-519", "generic_name": "BUPROPION HYDROCHLORIDE", "labeler_name": "BluePoint Laboratories", "product_type": "HUMAN PRESCRIPTION DRUG", "brand_name_base": "BUPROPION HYDROCHLORIDE", "active_ingredients": [{"name": "BUPROPION HYDROCHLORIDE", "strength": "150 mg/1"}], "application_number": "ANDA210497", "marketing_category": "ANDA", "marketing_start_date": "20211213", "listing_expiration_date": "20261231"}